Trial intelligence / Profile preview

Safety study of MenACYW versus MENVEO given with routine pediatric vaccines in infants and toddlers

2019-004459-35Phase 3

Sponsor
Sanofi
Start
Feb 2020
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised trial of Meningococcal conjugate vaccine quadrivalent and meningococcal A conjugate vaccine in meningococcal disease (2 arms), sponsored by Sanofi. Primary endpoint: Solicited injection site and systemic reactions.

02

Drugs

Meningococcal conjugate vaccine quadrivalentmeningococcal A conjugate vaccine
03

Conditions

meningococcal disease

Beyond the preview

Go deeper on 2019-004459-35.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2019-004459-35.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call